Dianthus Therapeutics announced Q1 2026 financial results and key business updates, including an early go decision in their Phase 3 CAPTIVATE trial for claseprubart in CIDP after achieving 20 responders early. The company is on track to start a Phase 3 trial for generalized Myasthenia Gravis mid-2026 and expects top-line results by late 2028. They also continue Phase 2 trials for Multifocal Motor Neuropathy and Phase 1 trials for DNTH212 targeting rheumatology diseases. Dianthus strengthened its cash position to approximately $1.2 billion after raising $719 million in a public offering, providing runway into 2030. These developments position Dianthus to advance its pipeline of next-generation autoimmune therapies.
The global pharmaceutical surfactants market, valued at $4.5 billion in 2025, is projected to grow to $6.93 billion by 2035 at a CAGR of 4.42%. Growth is fueled by increasing use in drug formulation to enhance solubility, stability, and bioavailabili...
Noble Corporation reported weaker-than-expected revenue and earnings per share for Q2 2026 due to vessel suspensions and contract completions. Despite lowering its full-year 2026 guidance, the company maintains a strong backlog of $6.8 billion and ri...
Bitcoin fell more than 3% to around $63,494, hitting a 10-day low as tech stocks tied to AI plunged, notably South Korea's KOSPI dropping over 10%. This sell-off spread to digital assets, with Ethereum, Solana, and XRP also declining. Market uncertai...
CoinMarketCap's Altcoin Season Index increased to 53, indicating a slight improvement in altcoin performance relative to Bitcoin. However, this level remains below the 75 threshold that signals a full altcoin season, keeping the market in a neutral s...
Unilever reported its strongest quarterly volume growth in more than ten years, with underlying sales rising 5.8% in Q2, surpassing analyst expectations. Sales volumes increased 5.5%, and revenue reached €13.05 billion, beating forecasts. The company...
